Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial — SGMT Stock Surges Pre-Market

Shares of Sagimet Biosciences (SGMT) rose 13% in pre-market trading on Wednesday after the biotech firm reported promising long-term results for its experimental acne drug and raised fresh capital to fund its upcoming U.S. Phase 3 trial.Sagimet’s Denifanstat produced a 57% treatment-success rate af…